Generated by AI
Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing platform. The company works on therapies designed to make targeted, single-letter changes in DNA without creating double-strand breaks, supporting programs aimed at serious genetic and hematologic diseases. Its current pipeline includes research and clinical candidates across areas such as blood disorders, liver diseases, and other rare conditions. Beam Therapeutics also maintains integrated capabilities in gene editing, delivery, and internal manufacturing to support the development of its therapeutic candidates. Based in Cambridge, Massachusetts, Beam Therapeutics plays a role in the advanced genomics and gene-editing market, where precision medicine approaches are being applied to address diseases with limited treatment options.
Website238 Main Street
Cambridge, MA, 02142
United States
The latest articles about BEAM.
Beam Therapeutics (BEAM) just crossed a major clinical hurdle. The firm reported that its sickle cell therapy candidate, ristoglogene autogetemcel, met all primary and secondary endpoints in the BEACON Phase 1/2 trial. Beam Therapeutics has not seen that clinical success translate into short term share price strength, with the stock down 6.9% on a 1 day basis and weaker over the past week, month and quarter. However, the 1 year total shareholder return of 11.9% and 3 year total shareholder...
Summary of Nov 16's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
Summary of Oct 30's posts. Generated by AI.
Investors talking about BEAM also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.